Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals' stock has shown impressive momentum with a 63% gain over the past six months. TD Cowen raised its price target to $60, citing stronger adoption of Onapgo and strong market performance of Qelbree. Piper Sandler upgraded the company to "Overweight" with a price target of $65, driven by Onapgo's sales potential. Cantor Fitzgerald increased its price target to $63, citing faster adoption of Onapgo, and Zacks Research upgraded Supernus Pharmaceuticals to a "strong-buy" rating. Stifel raised its price target to $43 following strong second-quarter 2025 performance, where revenues reached $165.5 million. The company reported Q2 2025 results topping revenue expectations, with GAAP profit significantly above estimates. Net sales of Qelbree increased 31% and Gocovri increased 16% in Q2 2025 compared to the same period in 2024. Onapgo was launched in April 2025. The company also completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025. Insider selling activity was noted, with CEO Jack A. Khattar and CFO Timothy C. Dec selling shares in August and October. Supernus Pharmaceuticals reported Q1 revenues of $149.8 million, up 4.3% year-on-year, exceeding analysts' expectations.

Demand for Supernus Pharmaceuticals' products, which treat chronic neurological and psychiatric conditions, is generally stable throughout the year due to ongoing patient needs. New product launches and increased prescriber adoption can drive significant growth in demand. Qelbree has shown consistent growth in prescriptions and net sales, with growth in both pediatric and adult businesses, and Gocovri also continued strong performance. The heightened interest in Onapgo for advanced Parkinson's disease suggests a potential for significant market demand.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system diseases, operating within the pharmaceuticals and healthcare sector. Its product portfolio includes treatments for ADHD, dyskinesia and hypomobility in Parkinson's Disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Major products include Qelbree, Gocovri, Onapgo, Oxtellar XR, Trokendi XR, Apokyn, Xadago, Myobloc, and Zurzuvae.

Supernus Pharmaceuticals is headquartered in Rockville, Maryland, and primarily markets its products in the United States. The company collaborates with channel partners to license its products outside the US. It also has locations and subsidiaries including Supernus Europe Ltd. in the United Kingdom, Biscayne Neurotherapeutics Australia Pty Ltd. in Australia, and Adamas Pharmaceuticals Inc. within the United States.

Supernus Pharmaceuticals maintains a "GREAT" financial health score according to InvestingPro. The company is recognized for its focus on innovating CNS treatments and improving lives through neurological and psychiatric solutions. Analysts have a generally positive outlook, with a consensus "Buy" rating and an average target price of $62.67. The company's reputation has been bolstered by strong product launches and performance, particularly with Qelbree, Gocovri, and Onapgo. The acquisition of Sage Therapeutics, Inc. in July 2025 is seen as a strategic move to accelerate mid to long-term revenue growth and cash flow, further diversifying its revenue base with products like Zurzuvae. However, there have been some mixed reviews, including a "hold (c)" rating from Weiss Ratings and a downgrade from "buy" to "hold" from Wall Street Zen in October 2025. Insider selling activity by the CEO and CFO could also be perceived as a potential shift in confidence among executive management.

Approximately 8.80% of Supernus Pharmaceuticals' stock is owned by corporate insiders. AlphaQuest LLC bought an additional 17,523 shares, bringing their total to 22,391 shares. Bank of Montreal Can raised its position by 4.9% in the second quarter, now owning 10,144 shares. Vident Advisory LLC raised its position by 3.4% in the first quarter, now owning 14,886 shares. Yousif Capital Management LLC raised its position by 1.5% in the second quarter, now owning 21,032 shares. GAMMA Investing LLC raised its holdings by 116.7% during the second quarter, now owning 2,861 shares. CWM LLC raised its holdings by 92.4% during the second quarter, now owning 3,080 shares. Caitong International Asset Management Co. Ltd bought a new position in the first quarter. Key individual owners include CEO Jack A. Khattar, who owned 1,206,578 shares after a sale in October 2025, and CFO Timothy C. Dec, who owned 1,246 shares after a sale in August 2025. SVP Frank Mottola also sold shares in August 2025, reducing his ownership.